Is Netflix a Must-own Stock?
The early months of 2025 have been very hard on…
Buy
76
TGTX Quote, Financials, Valuation and Earnings
Last price:
$41.31
Seasonality move
:
12.75%
Day range:
$39.41 - $41.08
52-week range:
$12.93 - $43.32
Dividend yield:
0%
P/E ratio:
287.86x
P/S ratio:
19.19x
P/B ratio:
28.47x
Volume:
2.4M
Avg. volume:
2.9M
1-year change:
188.27%
Market cap:
$6.3B
Revenue:
$329M
EPS (TTM):
$0.14
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TGTX
TG Therapeutics
|
$117.9M | $0.17 | 77.29% | 743.75% | $43.00 |
|
ADMA
ADMA Biologics
|
$116.4M | $0.14 | 42.17% | 75% | $25.74 |
|
CARA:DL
Cara Therapeutics(DELISTED)
|
-- | -- | 813.82% | -- | -- |
|
CMRX
Chimerix
|
-- | -$0.27 | 7665% | -8% | $8.53 |
|
OCGN
Ocugen
|
-- | -$0.06 | -100% | -- | $6.75 |
|
OCUL
Ocular Therapeutix
|
$16.9M | -$0.28 | 16.58% | -42.86% | $17.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TGTX
TG Therapeutics
|
$40.30 | $43.00 | $6.3B | 287.86x | $0.00 | 0% | 19.19x |
|
ADMA
ADMA Biologics
|
$22.33 | $25.74 | $5.3B | 27.23x | $0.00 | 0% | 12.72x |
|
CARA:DL
Cara Therapeutics(DELISTED)
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
CMRX
Chimerix
|
$8.54 | $8.53 | $801.1M | -- | $0.00 | 0% | -- |
|
OCGN
Ocugen
|
$0.74 | $6.75 | $215.2M | -- | $0.00 | 0% | 49.24x |
|
OCUL
Ocular Therapeutix
|
$7.90 | $17.50 | $1.3B | -- | $0.00 | 0% | 19.62x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TGTX
TG Therapeutics
|
52.36% | 1.750 | 5.21% | 4.85x |
|
ADMA
ADMA Biologics
|
17.17% | 2.782 | 1.78% | 2.76x |
|
CARA:DL
Cara Therapeutics(DELISTED)
|
-- | -3.140 | -- | -- |
|
CMRX
Chimerix
|
-- | -9.573 | -- | 5.55x |
|
OCGN
Ocugen
|
49.18% | 1.424 | 12.22% | 2.71x |
|
OCUL
Ocular Therapeutix
|
17.85% | 2.429 | 5.09% | 10.26x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TGTX
TG Therapeutics
|
$92.8M | $29.9M | 6.86% | 12.81% | 30.05% | -$25.7M |
|
ADMA
ADMA Biologics
|
$63.3M | $38.3M | 60.85% | 93.41% | 31.98% | $47.5M |
|
CARA:DL
Cara Therapeutics(DELISTED)
|
-- | -- | -- | -- | -- | -- |
|
CMRX
Chimerix
|
-- | -$24.6M | -56.64% | -56.65% | -43073.68% | -$19.4M |
|
OCGN
Ocugen
|
-- | -$13.8M | -136.46% | -171.04% | -1811.52% | -$10.4M |
|
OCUL
Ocular Therapeutix
|
$15.9M | -$50.6M | -51.22% | -62.66% | -265.09% | -$39.6M |
TG Therapeutics vs. Competitors
-
Which has Higher Returns TGTX or ADMA?
ADMA Biologics has a net margin of 21.57% compared to TG Therapeutics's net margin of 95.19%. TG Therapeutics's return on equity of 12.81% beat ADMA Biologics's return on equity of 93.41%.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics85.77% $0.15 $466.8M ADMAADMA Biologics53.88% $0.46 $421.4M -
What do Analysts Say About TGTX or ADMA?
TG Therapeutics has a consensus price target of $43.00, signalling upside risk potential of 6.7%. On the other hand ADMA Biologics has an analysts' consensus of $25.74 which suggests that it could grow by 15.27%. Given that ADMA Biologics has higher upside potential than TG Therapeutics, analysts believe ADMA Biologics is more attractive than TG Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics5 0 0 ADMAADMA Biologics3 1 0 -
Is TGTX or ADMA More Risky?
TG Therapeutics has a beta of 2.139, which suggesting that the stock is 113.867% more volatile than S&P 500. In comparison ADMA Biologics has a beta of 0.527, suggesting its less volatile than the S&P 500 by 47.277%.
-
Which is a Better Dividend Stock TGTX or ADMA?
TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. ADMA Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or ADMA?
TG Therapeutics quarterly revenues are $108.2M, which are smaller than ADMA Biologics quarterly revenues of $117.5M. TG Therapeutics's net income of $23.3M is lower than ADMA Biologics's net income of $111.9M. Notably, TG Therapeutics's price-to-earnings ratio is 287.86x while ADMA Biologics's PE ratio is 27.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 19.19x versus 12.72x for ADMA Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics19.19x 287.86x $108.2M $23.3M ADMAADMA Biologics12.72x 27.23x $117.5M $111.9M
-
Which has Higher Returns TGTX or CARA:DL?
Cara Therapeutics(DELISTED) has a net margin of 21.57% compared to TG Therapeutics's net margin of --. TG Therapeutics's return on equity of 12.81% beat Cara Therapeutics(DELISTED)'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics85.77% $0.15 $466.8M CARA:DLCara Therapeutics(DELISTED)-- -- -- -
What do Analysts Say About TGTX or CARA:DL?
TG Therapeutics has a consensus price target of $43.00, signalling upside risk potential of 6.7%. On the other hand Cara Therapeutics(DELISTED) has an analysts' consensus of -- which suggests that it could fall by --. Given that TG Therapeutics has higher upside potential than Cara Therapeutics(DELISTED), analysts believe TG Therapeutics is more attractive than Cara Therapeutics(DELISTED).
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics5 0 0 CARA:DLCara Therapeutics(DELISTED)0 0 0 -
Is TGTX or CARA:DL More Risky?
TG Therapeutics has a beta of 2.139, which suggesting that the stock is 113.867% more volatile than S&P 500. In comparison Cara Therapeutics(DELISTED) has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.556%.
-
Which is a Better Dividend Stock TGTX or CARA:DL?
TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cara Therapeutics(DELISTED) offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. Cara Therapeutics(DELISTED) pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or CARA:DL?
TG Therapeutics quarterly revenues are $108.2M, which are larger than Cara Therapeutics(DELISTED) quarterly revenues of --. TG Therapeutics's net income of $23.3M is higher than Cara Therapeutics(DELISTED)'s net income of --. Notably, TG Therapeutics's price-to-earnings ratio is 287.86x while Cara Therapeutics(DELISTED)'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 19.19x versus -- for Cara Therapeutics(DELISTED). Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics19.19x 287.86x $108.2M $23.3M CARA:DLCara Therapeutics(DELISTED)-- -- -- --
-
Which has Higher Returns TGTX or CMRX?
Chimerix has a net margin of 21.57% compared to TG Therapeutics's net margin of -40270.18%. TG Therapeutics's return on equity of 12.81% beat Chimerix's return on equity of -56.65%.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics85.77% $0.15 $466.8M CMRXChimerix-- -$0.25 $121.7M -
What do Analysts Say About TGTX or CMRX?
TG Therapeutics has a consensus price target of $43.00, signalling upside risk potential of 6.7%. On the other hand Chimerix has an analysts' consensus of $8.53 which suggests that it could fall by -0.18%. Given that TG Therapeutics has higher upside potential than Chimerix, analysts believe TG Therapeutics is more attractive than Chimerix.
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics5 0 0 CMRXChimerix0 2 0 -
Is TGTX or CMRX More Risky?
TG Therapeutics has a beta of 2.139, which suggesting that the stock is 113.867% more volatile than S&P 500. In comparison Chimerix has a beta of -0.176, suggesting its less volatile than the S&P 500 by 117.551%.
-
Which is a Better Dividend Stock TGTX or CMRX?
TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Chimerix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. Chimerix pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or CMRX?
TG Therapeutics quarterly revenues are $108.2M, which are larger than Chimerix quarterly revenues of $57K. TG Therapeutics's net income of $23.3M is higher than Chimerix's net income of -$23M. Notably, TG Therapeutics's price-to-earnings ratio is 287.86x while Chimerix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 19.19x versus -- for Chimerix. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics19.19x 287.86x $108.2M $23.3M CMRXChimerix-- -- $57K -$23M
-
Which has Higher Returns TGTX or OCGN?
Ocugen has a net margin of 21.57% compared to TG Therapeutics's net margin of -1816.75%. TG Therapeutics's return on equity of 12.81% beat Ocugen's return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics85.77% $0.15 $466.8M OCGNOcugen-- -$0.05 $58.3M -
What do Analysts Say About TGTX or OCGN?
TG Therapeutics has a consensus price target of $43.00, signalling upside risk potential of 6.7%. On the other hand Ocugen has an analysts' consensus of $6.75 which suggests that it could grow by 816%. Given that Ocugen has higher upside potential than TG Therapeutics, analysts believe Ocugen is more attractive than TG Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics5 0 0 OCGNOcugen2 0 0 -
Is TGTX or OCGN More Risky?
TG Therapeutics has a beta of 2.139, which suggesting that the stock is 113.867% more volatile than S&P 500. In comparison Ocugen has a beta of 3.784, suggesting its more volatile than the S&P 500 by 278.402%.
-
Which is a Better Dividend Stock TGTX or OCGN?
TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or OCGN?
TG Therapeutics quarterly revenues are $108.2M, which are larger than Ocugen quarterly revenues of $764K. TG Therapeutics's net income of $23.3M is higher than Ocugen's net income of -$13.9M. Notably, TG Therapeutics's price-to-earnings ratio is 287.86x while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 19.19x versus 49.24x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics19.19x 287.86x $108.2M $23.3M OCGNOcugen49.24x -- $764K -$13.9M
-
Which has Higher Returns TGTX or OCUL?
Ocular Therapeutix has a net margin of 21.57% compared to TG Therapeutics's net margin of -283.27%. TG Therapeutics's return on equity of 12.81% beat Ocular Therapeutix's return on equity of -62.66%.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics85.77% $0.15 $466.8M OCULOcular Therapeutix92.8% -$0.29 $383.8M -
What do Analysts Say About TGTX or OCUL?
TG Therapeutics has a consensus price target of $43.00, signalling upside risk potential of 6.7%. On the other hand Ocular Therapeutix has an analysts' consensus of $17.50 which suggests that it could grow by 121.52%. Given that Ocular Therapeutix has higher upside potential than TG Therapeutics, analysts believe Ocular Therapeutix is more attractive than TG Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics5 0 0 OCULOcular Therapeutix6 0 0 -
Is TGTX or OCUL More Risky?
TG Therapeutics has a beta of 2.139, which suggesting that the stock is 113.867% more volatile than S&P 500. In comparison Ocular Therapeutix has a beta of 1.491, suggesting its more volatile than the S&P 500 by 49.133%.
-
Which is a Better Dividend Stock TGTX or OCUL?
TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. Ocular Therapeutix pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or OCUL?
TG Therapeutics quarterly revenues are $108.2M, which are larger than Ocular Therapeutix quarterly revenues of $17.1M. TG Therapeutics's net income of $23.3M is higher than Ocular Therapeutix's net income of -$48.4M. Notably, TG Therapeutics's price-to-earnings ratio is 287.86x while Ocular Therapeutix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 19.19x versus 19.62x for Ocular Therapeutix. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics19.19x 287.86x $108.2M $23.3M OCULOcular Therapeutix19.62x -- $17.1M -$48.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Bill Ackman Buy Uber Stock?
In February, Pershing Square manager Bill Ackman revealed that his…
Should You Buy Alibaba Stock Despite the Risks?
Markets rebounded slightly after U.S. President Donald Trump announced a…
Stock Ideas
Buy
59
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.6T
P/E Ratio: 36x
Alerts
Sell
48
FI alert for Apr 25
Fiserv [FI] is up 0.33% over the past day.
Buy
66
FARO alert for Apr 25
Faro Technologies [FARO] is up 0.93% over the past day.
Buy
55
PI alert for Apr 25
Impinj [PI] is up 2.15% over the past day.
